Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Current Treatment Options in Gastroenterology
Published in: Current Treatment Options in Gastroenterology 3/2018

Open Access 01-09-2018 | Endoscopy (P Siersema, Section Editor)

Management of Intraductal Papillary Mucinous Neoplasms: Controversies in Guidelines and Future Perspectives

Authors: IJM Levink, MD, MJ Bruno, MD, PhD, DL Cahen, MD, PhD

Published in: Current Treatment Options in Gastroenterology | Issue 3/2018

Login to get access

Abstract

Purpose of review

Management of intraductal papillary mucinous neoplasm (IPMN) is currently based on consensus, in the absence of evidence-based guidelines. In recent years, several consensus guidelines have been published, with distinct management strategies. In this review, we will discuss these discrepancies, in order to guide treating physicians in clinical management.

Recent findings

The detection rate of pancreatic cysts has increased substantially with the expanded use of high-quality imaging techniques to up to 45%. Of these cysts, 24–82% are IPMNs, which harbour a malignant potential. Timely detection of high-risk lesions is therefore of great importance. Surgical management is based on the presence of clinical and morphological high-risk features, yet the majority of resected specimens appear to be low risk.

Summary

International collaboration and incentive large-scale prospective registries of individuals undergoing cyst surveillance are needed to accumulate unbiased data and develop evidence-based guidelines. Additionally, development of non-invasive, accurate diagnostic tools (e.g. biomarkers) is needed to differentiate between neoplastic and non-neoplastic pancreatic cysts and detect malignant transformation at an early stage (i.e. high-grade dysplasia).
Literature
1.
Ohhashi K. Four cases of mucous secreting pancreatic cancer. Prog Dis Endosc. 1982;20:348–51.
2.
Sessa F, Solcia E, Capella C, Bonato M, Scarpa A, Zamboni G, et al. Intraductal papillary-mucinous tumours represent a distinct group of pancreatic neoplasms: an investigation of tumour cell differentiation and K-ras, p53 and c-erbB-2 abnormalities in 26 patients. Virchows Arch. 1994;425:357–67.PubMedCrossRef
3.
Tulla KA, Maker AV. Can we better predict the biologic behavior of incidental IPMN? A comprehensive analysis of molecular diagnostics and biomarkers in intraductal papillary mucinous neoplasms of the pancreas. Langenbeck’s Arch Surg. 2017.
4.
• Tanaka M, Chari S, Adsay V, Fernandez-del Castillo C, Falconi M, Shimizu M, et al. International consensus guidelines for management of intraductal papillary mucinous neoplasms and mucinous cystic neoplasms of the pancreas. Pancreatology. 2006;6:17–32. The first multidisciplinary consensus guidelines on the clinical management of pancreatic cysts and defined high-risk features (mural nodule, main-duct dilation, size > 3 cm) related to increased risk of malignant progression.PubMedCrossRef
5.
• Tanaka M, Fernandez-del Castillo C, Adsay V, et al. International consensus guidelines 2012 for the management of IPMN and MCN of the pancreas. Pancreatology. 2012;12:183–97. In response to their publication in 2006, extensive research led to new insights and the dichotomization of risk stratification (‘high-risk’ and ‘worrisome’ features). Recommending immediate resection in the case of high-risk features and a conservative approach in the case of worrisome features. Surveillance intervals are based on the the size of the cyst.PubMedCrossRef
6.
• Tanaka M, Fernandez-Del Castillo C, Kamisawa T, et al. Revisions of international consensus Fukuoka guidelines for the management of IPMN of the pancreas. Pancreatology. 2017;17:738–53. In 2017, the International Association of Pancreatology performed minor revisions and updates according to recent literature. High-risk stigmata remained the same, yet some worrisome features (e.g. lymphadenopathy, CA19-9 levels and cyst growth rate) were added.PubMedCrossRef
7.
• Elta GH, Enestvedt BK, Sauer BG, Marie Lennon A. ACG clinical guideline: diagnosis and management of pancreatic cysts. Am J Gastroenterol. 2018;113:464–79. With the increased quality of imaging modalities and the subsequent prevalent detection of pancreatic cysts came more guidelines. The ACG guidelines used describe 11 ‘high-risk characteristics’ of which seven characteristics indicate surgery.PubMedCrossRef
8.
• Vege SS, Ziring B, Jain R, et al. American Gastroenterological Association Institute guideline on the diagnosis and management of asymptomatic neoplastic pancreatic cysts. Gastroenterology. 2015;148:819–22. These AGA guidelines defined three high-risk features (solid component in the cyst, dilated MPD and cysts size ≥ 3 cm). These guidelines led to discussion due to their recommendation to discontinue surveillance in the case of no significant change of cyst during 5 years follow-up.PubMedCrossRef
9.
• Del Chiaro M, Verbeke C, Salvia R, et al. European experts consensus statement on cystic tumours of the pancreas. Dig Liver Dis. 2013;45:703–11. The European respond to the Tanaka guidelines, distingishuing absolute and relative indications for surgery and simplified the surveillance intervals to 6 months in the first year and yearly afterwards.PubMedCrossRef
10.
• European evidence-based guidelines on pancreatic cystic neoplasms. Gut 2018. The most recent guidelines, advocating an international workgroup (together with AGA, ACG, IAP) for the publication of one future worldwide guideline.
11.
Lee SY, Lee KT, Lee JK, et al. Long-term follow up results of intraductal papillary mucinous tumors of pancreas. J Gastroenterol Hepatol. 2005;20:1379–84.PubMedCrossRef
12.
Crippa S, Fernandez-Del Castillo C, Salvia R, et al. Mucin-producing neoplasms of the pancreas: an analysis of distinguishing clinical and epidemiologic characteristics. Clin Gastroenterol Hepatol. 2010;8:213–9.PubMedCrossRef
13.
Hwang DW, Jang J-Y, Lee SE, Lim CS, Lee KU, Kim SW. Clinicopathologic analysis of surgically proven intraductal papillary mucinous neoplasms of the pancreas in SNUH: a 15-year experience at a single academic institution. Langenbeck’s Arch Surg. 2012;397:93–102.CrossRef
14.
Salvia R, Castillo CF-d, Bassi C, et al. Main-duct intraductal papillary mucinous neoplasms of the pancreas: clinical predictors of malignancy and long-term survival following resection. Ann Surg. 2004;239:678–87.PubMedPubMedCentralCrossRef
15.
Schnelldorfer T, Sarr MG, Nagorney DM, Zhang L, Smyrk TC, Qin R, et al. Experience with 208 resections for intraductal papillary mucinous neoplasm of the pancreas. Arch Surg. 2008;143:639–46. discussion 646
16.
Ohno E, Hirooka Y, Kawashima H, et al. Natural history of pancreatic cystic lesions: a multicenter prospective observational study for evaluating the risk of pancreatic cancer. J Gastroenterol Hepatol. 2017.
17.
Kim SC, Park KT, Lee YJ, Lee SS, Seo DW, Lee SK, et al. Intraductal papillary mucinous neoplasm of the pancreas: clinical characteristics and treatment outcomes of 118 consecutive patients from a single center. J Hepato-Biliary-Pancreat Surg. 2008;15:183–8.CrossRef
18.
Suzuki Y, Atomi Y, Sugiyama M, Isaji S, Inui K, Kimura W, et al. Cystic neoplasm of the pancreas: a Japanese multiinstitutional study of intraductal papillary mucinous tumor and mucinous cystic tumor. Pancreas. 2004;28:241–6.PubMedCrossRef
19.
Nagai K, Doi R, Kida A, et al. Intraductal papillary mucinous neoplasms of the pancreas: clinicopathologic characteristics and long-term follow-up after resection. World J Surg. 2008;32:271–8.PubMedCrossRef
20.
Schmidt CM, White PB, Waters JA, Yiannoutsos CT, Cummings OW, Baker M, et al. Intraductal papillary mucinous neoplasms: predictors of malignant and invasive pathology. Ann Surg. 2007;246:644–51. discussion 651–4
21.
Yu S, Takasu N, Watanabe T, Fukumoto T, Okazaki S, Tezuka K, et al. Validation of the 2012 Fukuoka consensus guideline for intraductal papillary mucinous neoplasm of the pancreas from a single institution experience. Pancreas. 2017;46:936–42.PubMedCrossRef
22.
Abdeljawad K, Vemulapalli KC, Schmidt CM, Dewitt J, Sherman S, Imperiale TF, et al. Prevalence of malignancy in patients with pure main duct intraductal papillary mucinous neoplasms. Gastrointest Endosc. 2014;79:623–9.PubMedCrossRef
23.
Fritz S, Klauss M, Bergmann F, Strobel O, Schneider L, Werner J, et al. Pancreatic main-duct involvement in branch-duct IPMNs: an underestimated risk. Ann Surg. 2014;260:848–55. discussion 855–6
24.
Kang MJ, Jang JY, Lee KB, Chang YR, Kwon W, Kim SW. Long-term prospective cohort study of patients undergoing pancreatectomy for intraductal papillary mucinous neoplasm of the pancreas: implications for postoperative surveillance. Ann Surg. 2014;260:356–63.PubMedCrossRef
25.
Furukawa T, Hatori T, Fujita I, Yamamoto M, Kobayashi M, Ohike N, et al. Prognostic relevance of morphological types of intraductal papillary mucinous neoplasms of the pancreas. Gut. 2011;60:509–16.PubMedCrossRef
26.
Shimizu Y, Yamaue H, Maguchi H, Yamao K, Hirono S, Osanai M, et al. Predictors of malignancy in intraductal papillary mucinous neoplasm of the pancreas: analysis of 310 pancreatic resection patients at multiple high-volume centers. Pancreas. 2013;42:883–8.PubMedCrossRef
27.
Lafemina J, Katabi N, Klimstra D, et al. Malignant progression in IPMN: a cohort analysis of patients initially selected for resection or observation. Ann Surg Oncol. 2013;20:440–7.PubMedCrossRef
28.
Koh YX, Zheng HL, Chok AY, Tan CS, Wyone W, Lim TKH, et al. Systematic review and meta-analysis of the spectrum and outcomes of different histologic subtypes of noninvasive and invasive intraductal papillary mucinous neoplasms. Surgery. 2015;157:496–509.PubMedCrossRef
29.
Castellano-Megias VM, Andres CI, Lopez-Alonso G, et al. Pathological features and diagnosis of intraductal papillary mucinous neoplasm of the pancreas. World J Gastrointest Oncol. 2014;6:311–24.PubMedPubMedCentralCrossRef
30.
Furukawa T, Kloppel G, Volkan Adsay N, et al. Classification of types of intraductal papillary-mucinous neoplasm of the pancreas: a consensus study. Virchows Arch. 2005;447:794–9.PubMedCrossRef
31.
Ridtitid W, DeWitt JM, Schmidt CM, et al. Management of branch-duct intraductal papillary mucinous neoplasms: a large single-center study to assess predictors of malignancy and long-term outcomes. Gastrointest Endosc. 2016;84:436–45.PubMedCrossRef
32.
Aune D, Greenwood DC, Chan DSM, Vieira R, Vieira AR, Navarro Rosenblatt DA, et al. Body mass index, abdominal fatness and pancreatic cancer risk: a systematic review and non-linear dose–response meta-analysis of prospective studies. Ann Oncol. 2012;23:843–52.PubMedCrossRef
33.
Smits MM, van Geenen EJ. The clinical significance of pancreatic steatosis. Nat Rev Gastroenterol Hepatol. 2011;8:169–77.PubMedCrossRef
34.
Sturm EC, Roch AM, Shaffer KM, Schmidt CM II, Lee SJ, Zyromski NJ, et al. Obesity increases malignant risk in patients with branch-duct intraductal papillary mucinous neoplasm. Surgery. 2013;154:803–8. discussion 808–9
35.
Capurso G, Boccia S, Salvia R, et al. Risk factors for intraductal papillary mucinous neoplasm (IPMN) of the pancreas: a multicentre case–control study. Am J Gastroenterol. 2013;108:1003–9.PubMedCrossRef
36.
Marchegiani G, Malleo G, D’Haese JG, et al. Association between pancreatic intraductal papillary mucinous neoplasms and extrapancreatic malignancies. Clin Gastroenterol Hepatol. 2015;13:1162–9.PubMedCrossRef
37.
Moris M, Raimondo M, Woodward TA, Skinner V, Arcidiacono PG, Petrone MC, et al. Diagnostic accuracy of endoscopic ultrasound-guided fine-needle aspiration cytology, carcinoembryonic antigen, and amylase in intraductal papillary mucinous neoplasm. Pancreas. 2016;45:870–5.PubMedCrossRef
38.
Morales-Oyarvide V, Mino-Kenudson M, Ferrone CR, Sahani DV, Pergolini I, Negreros-Osuna AA, et al. Diabetes mellitus in intraductal papillary mucinous neoplasm of the pancreas is associated with high-grade dysplasia and invasive carcinoma. Pancreatology. 2017;17:920–6.PubMedCrossRef
39.
Kobayashi G, Fujita N, Noda Y, Ito K, Horaguchi J, Obana T, et al. Intraductal papillary mucinous neoplasms of the pancreas showing fistula formation into other organs. J Gastroenterol. 2010;45:1080–9.PubMedCrossRef
40.
Yamada Y, Mori H, Hijiya N, Matsumoto S, Takaji R, Ohta M, et al. Intraductal papillary mucinous neoplasms of the pancreas complicated with intraductal hemorrhage, perforation, and fistula formation: CT and MR imaging findings with pathologic correlation. Abdom Imaging. 2012;37:100–9.PubMedCrossRef
41.
Kimura W, Nagai H, Kuroda A, Muto T, Esaki Y. Analysis of small cystic lesions of the pancreas. Int J Pancreatol. 1995;18:197–206.PubMed
42.
Su Jin S, Jeong Min L, Young Jun K, et al. Differentiation of intraductal papillary mucinous neoplasms from other pancreatic cystic masses: comparison of multirow-detector CT and MR imaging using ROC analysis. J Magn Reson Imaging. 2007;26:86–93.CrossRef
43.
Rastegar N, Matteoni-Athayde LG, Eng J, et al. Incremental value of secretin-enhanced magnetic resonance cholangiopancreatography in detecting ductal communication in a population with high prevalence of small pancreatic cysts. Eur J Radiol. 2015;84:575–80.PubMedPubMedCentralCrossRef
44.
Harima H, Kaino S, Shinoda S, Kawano M, Suenaga S, Sakaida I. Differential diagnosis of benign and malignant branch duct intraductal papillary mucinous neoplasm using contrast-enhanced endoscopic ultrasonography. World J Gastroenterol. 2015;21:6252–60.PubMedPubMedCentralCrossRef
45.
Rodriguez-D’Jesus A, Fernandez-Esparrach G, Boadas J, et al. Impact of endoscopic ultrasonography (EUS) and EUS-guided fine-needle aspiration on the management of pancreatic cystic lesions. Eur J Gastroenterol Hepatol. 2016;28:1094–9.PubMedCrossRef
46.
Kamata K, Kitano M, Kudo M, Sakamoto H, Kadosaka K, Miyata T, et al. Value of EUS in early detection of pancreatic ductal adenocarcinomas in patients with intraductal papillary mucinous neoplasms. Endoscopy. 2014;46:22–9.PubMedCrossRef
47.
Javia S, Munigala S, Guha S, et al. EUS morphology is reliable in selecting patients with mucinous pancreatic cyst(s) most likely to benefit from surgical resection. Gastroenterol Res Pract. 2017;2017:9863952.PubMedPubMedCentralCrossRef
48.
Lu X, Zhang S, Ma C, Peng C, Lv Y, Zou X. The diagnostic value of EUS in pancreatic cystic neoplasms compared with CT and MRI. Endosc Ultrasound. 2015;4:324–9.PubMedPubMedCentralCrossRef
49.
van der Waaij LA, van Dullemen HM, Porte RJ. Cyst fluid analysis in the differential diagnosis of pancreatic cystic lesions: a pooled analysis. Gastrointest Endosc. 2005;62:383–9.PubMedCrossRef
50.
Suzuki R, Thosani N, Annangi S, Guha S, Bhutani MS. Diagnostic yield of EUS-FNA-based cytology distinguishing malignant and benign IPMNs: a systematic review and meta-analysis. Pancreatology. 2014;14:380–4.PubMedCrossRef
51.
Thosani N, Thosani S, Qiao W, Fleming JB, Bhutani MS, Guha S. Role of EUS-FNA based cytology in diagnosis of mucinous pancreatic cystic lesions: a systematic review and meta-analysis. Dig Dis Sci. 2010;55:2756–66.PubMedPubMedCentralCrossRef
52.
Rogart JN, Loren DE, Singu BS, Kowalski TE. Cyst wall puncture and aspiration during EUS-guided fine needle aspiration may increase the diagnostic yield of mucinous cysts of the pancreas. J Clin Gastroenterol. 2011;45:164–9.PubMedCrossRef
53.
Siddiqui AA, Shahid H, Shah A, Loren DE, Laique S, Eloubeidi MA, et al. High risk of acute pancreatitis after endoscopic ultrasound-guided fine needle aspiration of side branch intraductal papillary mucinous neoplasms. Endoscopic Ultrasound. 2015;4:109–14.PubMedPubMedCentralCrossRef
54.
O’Toole D, Palazzo L, Arotçarena R, Dancour A, Aubert A, Hammel P, et al. Assessment of complications of EUS-guided fine-needle aspiration. Gastrointest Endosc. 2001;53:470–4.PubMedCrossRef
55.
Hong S-KS, Loren DE, Rogart JN, Siddiqui AA, Sendecki JA, Bibbo M, et al. Targeted cyst wall puncture and aspiration during EUS-FNA increases the diagnostic yield of premalignant and malignant pancreatic cysts. Gastrointest Endosc. 2012;75:775–82.PubMedCrossRef
56.
Yoon WJ, Brugge WR. The safety of endoscopic ultrasound-guided fine-needle aspiration of pancreatic cystic lesions. Endoscopic Ultrasound. 2015;4:289–92.PubMedPubMedCentralCrossRef
57.
Polkowski M, Larghi A, Weynand B, Boustière C, Giovannini M, Pujol B, et al. Learning, techniques, and complications of endoscopic ultrasound (EUS)-guided sampling in gastroenterology: European Society of Gastrointestinal Endoscopy (ESGE) technical guideline. Endoscopy. 2012;44:190–206.PubMedCrossRef
58.
Hirono S, Tani M, Kawai M, Okada KI, Miyazawa M, Shimizu A, et al. The carcinoembryonic antigen level in pancreatic juice and mural nodule size are predictors of malignancy for branch duct type intraductal papillary mucinous neoplasms of the pancreas. Ann Surg. 2012;255:517–22.PubMedCrossRef
59.
Springer S, Wang Y, Dal Molin M, Masica DL, Jiao Y, Kinde I, et al. A combination of molecular markers and clinical features improve the classification of pancreatic cysts. Gastroenterology. 2015;149:1501–10.PubMedCrossRef
60.
Suenaga M, Yu J, Shindo K, Tamura K, Almario JA, Zaykoski C, et al. Pancreatic juice mutation concentrations can help predict the grade of dysplasia in patients undergoing pancreatic surveillance. Clin Cancer Res. 2018;24:2963–74.PubMedCrossRefPubMedCentral
61.
Jian S, William RB, Christopher JD, et al. Molecular analysis of pancreatic cyst fluid. Cancer Cytopathology. 2009;117:217–27.CrossRef
62.
Brugge WR, Lewandrowski K, Lee-Lewandrowski E, et al. Diagnosis of pancreatic cystic neoplasms: a report of the cooperative pancreatic cyst study. Gastroenterology. 2004;126:1330–6.PubMedCrossRef
63.
Oh HC, Kang H, Brugge WR. Cyst fluid amylase and CEA levels in the differential diagnosis of pancreatic cysts: a single-center experience with histologically proven cysts. Dig Dis Sci. 2014;59:3111–6.PubMedCrossRef
64.
65.
Kim YH, Saini S, Sahani D, Hahn PF, Mueller PR, Auh YH. Imaging diagnosis of cystic pancreatic lesions: pseudocyst versus nonpseudocyst. RadioGraphics. 2005;25:671–85.PubMedCrossRef
66.
Costa WL, Mantoan H, Brito RH, Ribeiro H, Diniz AL, Godoy A, et al. Pancreatic mucinous cystadenoma with serum CA 19–9 over 1,000,000 U/mL: a case report and review of the literature. World Journal of Surgical Oncology. 2015;13:78.PubMedPubMedCentralCrossRef
67.
Gold DV, Gaedcke J, Ghadimi BM, Goggins M, Hruban RH, Liu M, et al. PAM4 immunoassay alone and in combination with CA19-9 for the detection of pancreatic adenocarcinoma. Cancer. 2013;119:522–8.PubMedCrossRef
68.
Safi F, Schlosser W, Falkenreck S, Beger HG. Prognostic value of CA 19-9 serum course in pancreatic cancer. Hepatogastroenterology. 1998;45:253–9.PubMed
69.
Wang W, Zhang L, Chen L, et al. Serum carcinoembryonic antigen and carbohydrate antigen 19-9 for prediction of malignancy and invasiveness in intraductal papillary mucinous neoplasms of the pancreas: a meta-analysis. Biomed Rep. 2015;3:43–50.PubMedCrossRef
70.
Jae Ri K, Jin-Young J, Mee Joo K, et al. Clinical implication of serum carcinoembryonic antigen and carbohydrate antigen 19-9 for the prediction of malignancy in intraductal papillary mucinous neoplasm of pancreas. Journal of Hepato-Biliary-Pancreatic Sciences. 2015;22:699–707.CrossRef
71.
Wu J, Matthaei H, Maitra A, Dal Molin M, Wood LD, Eshleman JR, et al. Recurrent GNAS mutations define an unexpected pathway for pancreatic cyst development. Sci Transl Med. 2011;3:92ra66.PubMedPubMedCentralCrossRef
72.
Eliana A, Marco dal M, Andrea M, et al. Targeted next-generation sequencing of cancer genes dissects the molecular profiles of intraductal papillary neoplasms of the pancreas. J Pathol. 2014;233:217–27.CrossRef
73.
Hosoda W, Sasaki E, Murakami Y, Yamao K, Shimizu Y, Yatabe Y. GNAS mutation is a frequent event in pancreatic intraductal papillary mucinous neoplasms and associated adenocarcinomas. Virchows Arch. 2015;466:665–74.PubMedCrossRef
74.
Lee JH, Kim Y, Choi JW, Kim YS. KRAS, GNAS, and RNF43 mutations in intraductal papillary mucinous neoplasm of the pancreas: a meta-analysis. Springerplus. 2016;5:1172.PubMedPubMedCentralCrossRef
75.
Molin MD, Matthaei H, Wu J, et al. Clinicopathological correlates of activating GNAS mutations in intraductal papillary mucinous neoplasm (IPMN) of the pancreas. Ann Surg Oncol. 2013;20:3802–8.PubMedCrossRef
76.
Kanda M, Matthaei H, Wu J, Hong S–M, Yu J, Borges M, et al. Presence of somatic mutations in most early-stage pancreatic intraepithelial neoplasia. Gastroenterology. 2012;142:730–733.e9.PubMedCrossRef
77.
Berger AW, Schwerdel D, Costa IG, et al. Detection of hot-spot mutations in circulating cell-free DNA from patients with intraductal papillary mucinous neoplasms of the pancreas. Gastroenterology. 2016;151:267–70.PubMedCrossRef
78.
Yang S, Che SP, Kurywchak P, et al. Detection of mutant KRAS and TP53 DNA in circulating exosomes from healthy individuals and patients with pancreatic cancer. Cancer Biol Ther. 2017;18:158–65.PubMedPubMedCentralCrossRef
79.
Yu J, Sadakari Y, Shindo K, Suenaga M, Brant A, Almario JAN, et al. Digital next-generation sequencing identifies low-abundance mutations in pancreatic juice samples collected from the duodenum of patients with pancreatic cancer and intraductal papillary mucinous neoplasms. Gut. 2017;66:1677–87.PubMedCrossRef
80.
Hara T, Yamaguchi T, Ishihara T, Tsuyuguchi T, Kondo F, Kato K, et al. Diagnosis and patient management of intraductal papillary-mucinous tumor of the pancreas by using peroral pancreatoscopy and intraductal ultrasonography. Gastroenterology. 2002;122:34–43.PubMedCrossRef
81.
Navez J, Hubert C, Gigot J-F, et al. Impact of intraoperative pancreatoscopy with intraductal biopsies on surgical management of intraductal papillary mucinous neoplasm of the pancreas. J Am Coll Surg. 221:982–7.
82.
Konda VJ, Meining A, Jamil LH, Giovannini M, Hwang JH, Wallace MB, et al. A pilot study of in vivo identification of pancreatic cystic neoplasms with needle-based confocal laser endomicroscopy under endosonographic guidance. Endoscopy. 2013;45:1006–13.PubMedCrossRef
83.
Nakai Y, Iwashita T, Park DH, Samarasena JB, Lee JG, Chang KJ. Diagnosis of pancreatic cysts: EUS-guided, through-the-needle confocal laser-induced endomicroscopy and cystoscopy trial: DETECT study. Gastrointest Endosc. 2015;81:1204–14.PubMedCrossRef
84.
Le Pen C, Palazzo L, Napoleon B. A health economic evaluation of needle-based confocal laser endomicroscopy for the diagnosis of pancreatic cysts. Endosc Int Open. 2017;5:E987–95.PubMedPubMedCentralCrossRef
85.
Napoleon B, Lemaistre AI, Pujol B, et al. A novel approach to the diagnosis of pancreatic serous cystadenoma: needle-based confocal laser endomicroscopy. Endoscopy. 2015;47:26–32.PubMedCrossRef
86.
Marchegiani G, Andrianello S, Borin A, Dal Borgo C, Perri G, Pollini T, et al. Systematic review, meta-analysis, and a high-volume center experience supporting the new role of mural nodules proposed by the updated 2017 international guidelines on IPMN of the pancreas. Surgery. 2018;163:1272–9.PubMedCrossRef
87.
Maimone S, Agrawal D, Pollack MJ, Wong RCK, Willis J, Faulx AL, et al. Variability in measurements of pancreatic cyst size among EUS, CT, and magnetic resonance imaging modalities. Gastrointest Endosc. 2010;71:945–50.PubMedCrossRef
88.
Walsh RM, Vogt DP, Henderson JM, Hirose KZ, Mason T, Bencsath K, et al. Management of suspected pancreatic cystic neoplasms based on cyst size. Surgery. 2008;144:677–84. discussion 684–5
89.
Jang JY, Kim SW, Lee SE, Yang SH, Lee KU, Lee YJ, et al. Treatment guidelines for branch duct type intraductal papillary mucinous neoplasms of the pancreas: when can we operate or observe? Ann Surg Oncol. 2008;15:199–205.PubMedCrossRef
90.
Weinberg BM, Spiegel BM, Tomlinson JS, et al. Asymptomatic pancreatic cystic neoplasms: maximizing survival and quality of life using Markov-based clinical nomograms. Gastroenterology. 2010;138:531–40.PubMedCrossRef
91.
Rautou PE, Levy P, Vullierme MP, et al. Morphologic changes in branch duct intraductal papillary mucinous neoplasms of the pancreas: a midterm follow-up study. Clin Gastroenterol Hepatol. 2008;6:807–14.PubMedCrossRef
92.
Kang MJ, Jang JY, Kim SJ, et al. Cyst growth rate predicts malignancy in patients with branch duct intraductal papillary mucinous neoplasms. Clin Gastroenterol Hepatol. 2011;9:87–93.PubMedCrossRef
93.
Kwong WT, Lawson RD, Hunt G, Fehmi SM, Proudfoot JA, Xu R, et al. Rapid growth rates of suspected pancreatic cyst branch duct intraductal papillary mucinous neoplasms predict malignancy. Dig Dis Sci. 2015;60:2800–6.PubMedCrossRef
94.
Boos J, Brook A, Chingkoe CM, Morrison T, Mortele K, Raptopoulos V, et al. MDCT vs. MRI for incidental pancreatic cysts: measurement variability and impact on clinical management. Abdominal Radiology. 2017;42:521–30.PubMedCrossRef
95.
Hackert T, Fritz S, Klauss M, Bergmann F, Hinz U, Strobel O, et al. Main-duct intraductal papillary mucinous neoplasm: high cancer risk in duct diameter of 5 to 9 mm. Ann Surg. 2015;262:875–81.PubMedCrossRef
96.
Kwong WT, Hunt GC, Fehmi SM, Honerkamp-Smith G, Xu R, Lawson RD, et al. Low rates of malignancy and mortality in asymptomatic patients with suspected neoplastic pancreatic cysts beyond 5 years of surveillance. Clin Gastroenterol Hepatol. 2016;14:865–71.PubMedCrossRef
97.
Khannoussi W, Vullierme MP, Rebours V, Maire F, Hentic O, Aubert A, et al. The long term risk of malignancy in patients with branch duct intraductal papillary mucinous neoplasms of the pancreas. Pancreatology. 2012;12:198–202.PubMedCrossRef
98.
Tanno S, Nakano Y, Nishikawa T, Nakamura K, Sasajima J, Minoguchi M, et al. Natural history of branch duct intraductal papillary-mucinous neoplasms of the pancreas without mural nodules: long-term follow-up results. Gut. 2008;57:339–43.PubMedCrossRef
99.
Farrell JJ, Fernández-del Castillo C. Pancreatic cystic neoplasms: management and unanswered questions. Gastroenterology. 2013;144:1303–15.PubMedCrossRef
100.
Del Chiaro M, Ateeb Z, Hansson MR, et al. Survival analysis and risk for progression of intraductal papillary mucinous neoplasia of the pancreas (IPMN) under surveillance: a single-institution experience. Ann Surg Oncol. 2017;24:1120–6.PubMedCrossRef
101.
He J, Cameron JL, Ahuja N, et al. Is it necessary to follow patients after resection of a benign pancreatic intraductal papillary mucinous neoplasm? J Am Coll Surg. 2013;216:657–65.PubMedPubMedCentralCrossRef
102.
Larghi A, Panic N, Capurso G, Leoncini E, Arzani D, Salvia R, et al. Prevalence and risk factors of extrapancreatic malignancies in a large cohort of patients with intraductal papillary mucinous neoplasm (IPMN) of the pancreas. Ann Oncol. 2013;24:1907–11.PubMedCrossRef
103.
Kato T, Alonso S, Noda H, et al. Malignant, but not benign, intraductal papillary mucinous neoplasm preferentially associates with prior extrapancreatic malignancies. Oncol Rep. 2016;35:3236–40.PubMedCrossRef
104.
Roch AM, Rosati CM, Cioffi JL, Ceppa EP, DeWitt JM, al-Haddad MA, et al. Intraductal papillary mucinous neoplasm of the pancreas, one manifestation of a more systemic disease? Am J Surg. 2016;211:512–8.PubMedCrossRef
105.
Baiocchi GL, Molfino S, Frittoli B, Pigozzi G, Gheza F, Gaverini G, et al. Increased risk of second malignancy in pancreatic intraductal papillary mucinous tumors: review of the literature. World J Gastroenterol. 2015;21:7313–9.PubMedPubMedCentralCrossRef
106.
de Wilde RF, Besselink MG, van der Tweel I, et al. Impact of nationwide centralization of pancreaticoduodenectomy on hospital mortality. Br J Surg. 2012;99:404–10.PubMedCrossRef
107.
Kawakubo K, Tada M, Isayama H, et al. Disease-specific mortality among patients with intraductal papillary mucinous neoplasm of the pancreas. Clin Gastroenterol Hepatol. 2014;12:486–91.PubMedCrossRef
108.
Reames BN, Ghaferi AA, Birkmeyer JD, Dimick JB. Hospital volume and operative mortality in the modern era. Ann Surg. 2014;260:244–51.PubMedCrossRef
109.
Vanella G, Crippa S, Archibugi L, Arcidiacono PG, Delle Fave G, Falconi M, et al. Meta-analysis of mortality in patients with high-risk intraductal papillary mucinous neoplasms under observation. Br J Surg. 2018;105:328–38.PubMedCrossRef
110.
Maker AV, Sheikh R, Bhagia V. Perioperative management of endocrine insufficiency after total pancreatectomy for neoplasia. Langenbeck’s Arch Surg. 2017;402:873–83.CrossRef
111.
Stauffer JA, Nguyen JH, Heckman MG, Grewal MS, Dougherty M, Gill KRS, et al. Patient outcomes after total pancreatectomy: a single centre contemporary experience. HPB : The Official Journal of the International Hepato Pancreato Biliary Association. 2009;11:483–92.CrossRef
112.
Waters JA, Schmidt CM, Pinchot JW, White PB, Cummings OW, Pitt HA, et al. CT vs MRCP: optimal classification of IPMN type and extent. J Gastrointest Surg. 2008;12:101–9.PubMedCrossRef
113.
Gleeson EM, Shaikh MF, Shewokis PA, Clarke JR, Meyers WC, Pitt HA, et al. WHipple-ABACUS, a simple, validated risk score for 30-day mortality after pancreaticoduodenectomy developed using the ACS-NSQIP database. Surgery. 2016;160:1279–87.PubMedCrossRef
114.
Marchegiani G, Mino-Kenudson M, Ferrone CR, Morales-Oyarvide V, Warshaw AL, Lillemoe KD, et al. Patterns of recurrence after resection of IPMN: who, when, and how? Ann Surg. 2015;262:1108–14.PubMedCrossRef
115.
Miller JR, Meyer JE, Waters JA, al-Haddad M, DeWitt J, Sherman S, et al. Outcome of the pancreatic remnant following segmental pancreatectomy for non-invasive intraductal papillary mucinous neoplasm. HPB : The Official Journal of the International Hepato Pancreato Biliary Association. 2011;13:759–66.CrossRef
116.
Yan L, Siddiqui AA, Laique SN, Saumoy M, Kahaleh M, Yoo J, et al. A large multicenter study of recurrence after surgical resection of branch-duct intraductal papillary mucinous neoplasm of the pancreas. Minerva Gastroenterol Dietol. 2017;63:50–4.PubMed
117.
Al Efishat M, Attiyeh MA, Eaton AA, et al. Progression patterns in the remnant pancreas after resection of non-invasive or micro-invasive intraductal papillary mucinous neoplasms (IPMN). Ann Surg Oncol. 2018.
118.
Raut CP, Cleary KR, Staerkel GA, Abbruzzese JL, Wolff RA, Lee JH, et al. Intraductal papillary mucinous neoplasms of the pancreas: effect of invasion and pancreatic margin status on recurrence and survival. Ann Surg Oncol. 2006;13:582–94.PubMedCrossRef
119.
Fujii T, Kato K, Kodera Y, et al. Prognostic impact of pancreatic margin status in the intraductal papillary mucinous neoplasms of the pancreas. Surgery. 2010;148:285–90.PubMedCrossRef
120.
Tamura K, Ohtsuka T, Ideno N, Aso T, Shindo K, Aishima S, et al. Treatment strategy for main duct intraductal papillary mucinous neoplasms of the pancreas based on the assessment of recurrence in the remnant pancreas after resection: a retrospective review. Ann Surg. 2014;259:360–8.PubMedCrossRef
121.
Rezaee N, Barbon C, Zaki A, et al. Intraductal papillary mucinous neoplasm (IPMN) with high-grade dysplasia is a risk factor for the subsequent development of pancreatic ductal adenocarcinoma. HPB. 2016;18:236–46.PubMedCrossRef
Metadata
Title
Management of Intraductal Papillary Mucinous Neoplasms: Controversies in Guidelines and Future Perspectives
Authors
IJM Levink, MD
MJ Bruno, MD, PhD
DL Cahen, MD, PhD
Publication date
01-09-2018
Publisher
Springer US
Published in
Current Treatment Options in Gastroenterology / Issue 3/2018
Print ISSN: 1092-8472
Electronic ISSN: 1534-309X
DOI
https://doi.org/10.1007/s11938-018-0190-2

Other articles of this Issue 3/2018

Current Treatment Options in Gastroenterology 3/2018 Go to the issue

Endoscopy (P Siersema, Section Editor)

Training in Endoscopy

Intractable Disease in the Elderly: When Conventional Therapy Fails (S Katz, Section Editor)

Outcomes and Management of the Ileal Pouch-Anal Anastomosis in the Elderly

Pancreas (V Chandrasekhara, Section Editor)

Diagnosis and Management of Exocrine Pancreatic Insufficiency

Intractable Disease in the Elderly: When Conventional Therapy Fails (S Katz, Section Editor)

Inflammatory Bowel Disease in the Baby to Baby Boomer: Pediatric and Elderly Onset of IBD

Endoscopy (P Siersema, Section Editor)

Endoscopic Management of Infected Necrotizing Pancreatitis: an Evidence-Based Approach
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits